Literature DB >> 11470383

SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health.

L Rabeneck1, K F Cook, K Wristers, J Souchek, T Menke, N P Wray.   

Abstract

The aim of this research was to develop and evaluate an instrument for measuring dyspepsia-related health to serve as the primary outcome measure for randomized clinical trials. Building on our previous work we developed SODA (Severity of Dyspepsia Assessment), a multidimensional dyspepsia measure. We evaluated SODA by administering it at enrollment and seven follow-up visits to 98 patients with dyspepsia who were randomized to a 6-week course of omeprazole versus placebo and followed over 1 year. The mean age was 53 years, and six patients (6%) were women. Median Cronbach's alpha reliability estimates over the eight visits for the SODA Pain Intensity, Non-Pain Symptoms, and Satisfaction scales were 0.97, 0.90, and 0.92, respectively. The mean change scores for all three scales discriminated between patients who reported they were improved versus those who were unchanged, providing evidence of validity. The effect sizes for the Pain Intensity (.98) and Satisfaction (.87) scales were large, providing evidence for responsiveness. The effect size for the Non-Pain Symptoms scale was small (.24), indicating lower responsiveness in this study sample. SODA is a new, effective instrument for measuring dyspepsia-related health. SODA is multidimensional and responsive to clinically meaningful change with demonstrated reliability and validity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470383     DOI: 10.1016/s0895-4356(00)00365-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  17 in total

1.  Functional dyspepsia.

Authors:  Rita Brun; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

2.  Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.

Authors:  Jay C Desai; Shefali M Sanyal; Tyralee Goo; Ariel A Benson; Carol A Bodian; Kenneth M Miller; Lawrence B Cohen; James Aisenberg
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

3.  Combination of symptoms, syndrome and disease: treatment of refractory diabetic gastroparesis.

Authors:  Jun-Ling Li; Min Li; Bing Pang; Qiang Zhou; Jia-Xing Tian; Hong-Xing Liu; Xi-Yan Zhao; Xiao-Lin Tong
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Authors:  M Vardi; B L Cryer; M Cohen; A Lanas; T J Schnitzer; P Lapuerta; M A Goldsmith; L Laine; G Doros; Y Liu; A I McIntosh; C P Cannon; D L Bhatt
Journal:  Aliment Pharmacol Ther       Date:  2015-05-29       Impact factor: 8.171

5.  Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders.

Authors:  A M Rentz; P Kahrilas; V Stanghellini; J Tack; N J Talley; C de la Loge; E Trudeau; D Dubois; D A Revicki
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

Review 6.  Patient assessment of treatment satisfaction: methods and practical issues.

Authors:  D A Revicki
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms.

Authors:  Dennis A Revicki; Anne M Rentz; Dominique Dubois; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack
Journal:  Qual Life Res       Date:  2004-05       Impact factor: 4.147

8.  Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial.

Authors:  A T Lassen; J Hallas; O B Schaffalitzky de Muckadell
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

9.  A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms.

Authors:  Douglas S Kalman; Howard I Schwartz; Patricia Alvarez; Samantha Feldman; John C Pezzullo; Diane R Krieger
Journal:  BMC Gastroenterol       Date:  2009-11-18       Impact factor: 3.067

10.  Effect of moderate aerobic exercises on symptoms of functional dyspepsia.

Authors:  Siddhesh Vijay Rane; Bharati Asgaonkar; Pravin Rathi; Qais Contractor; Sanjay Chandnani; Parmeshwar Junare; Prasanta Debnath; Vidya Bhat
Journal:  Indian J Gastroenterol       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.